American Association of Feline Practitioners 2006 Feline Vaccination Guidelines.  Summary: Vaccination in General Practice




Primary Series-Kittens

(< 16 weeks)

Primary Series-Adolescent/


(> 16 weeks)





Panleukopenia Virus (FPV) /Feline Herpesvirus-1 and Feline Calicivirus (FHV-1/FCV)


  • MLV, non-adjuvanted
  • Killed, adjuvanted[i] [i]
  • Killed, non-adjuvanted



  • MLV, non-adjuvanted

Begin as early as 6 weeks of age, then every 3-4 weeks until 16 weeks of age.

2 doses, 3 to 4 weeks apart

A single dose is given 1 year following the last dose of the initial series, then no more frequently than every 3 years.


  • Killed vaccines are preferred for use in pregnant cats (and only if absolutely necessary) and in FeLV and/or FIV infected cats, especially those showing evidence of immunosuppression.
  • Killed panleukopenia vaccines should be used in kittens less than 4 weeks of age.  
  • All kittens and cats should receive at least one injectable panleukopenia injection.








  • Canarypox virus-vectored recombinant (rRabies), non-adjuvanted
  • 1-year killed, adjuvanteda
  • 3-Year killed, adjuvanteda

Administer a single dose as early as 8 or 12 weeks of age depending on the product label. Revaccinate 1 year later.


Administer 2 doses, 12 months apart.

Annual booster is required.


Vs. Every 3 years or as required by State or local ordinance for 3-year


  • In States and municipalities where feline rabies vaccination is required, veterinarians must follow applicable statutes.
  • Booster vaccination with a 1-year rabies vaccine is only appropriate in States and municipalities where permitted by law.
  • Any rabies vaccine can be used for revaccination, even if the product is not the same brand or type of product previously administered. 
  • No laboratory or epidemiologic data exist to support the annual or biennial administration of 3-year vaccines following the initial series.

[i] [i] Injectable adjuvanted vaccines have been associated with local inflammatory reactions at injection sites, with the degree of inflammation varying among products.  The potential role of local inflammatory reactions in the genesis of vaccine-associated sarcomas remains controversial.